Cidara is a clinical stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives. Our pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical, and candidates generated by our Cloudbreak™ immunotherapy platform.
Recent News and Insights
Cidara seeks to improve patients’ lives through the discovery, development and commercialization of novel, best-in-class, anti-infectives. Our initial portfolio is comprised of proprietary product candidates for the treatment of serious fungal infections.
Fungal infections pose significant medical challenges in both the hospital and outpatient settings. These infections typically afflict immunocompromised persons including patients undergoing organ or bone marrow transplantation, chemotherapy, or patients with AIDS.
Our lead product candidate, CD101 IV, is a novel molecule in the echinocandin class of antifungals. We are initially developing CD101 IV for the treatment of systemic Candida infections. We have completed Phase 1 trials and plan to initiate a Phase 2 trial in the first half of 2016.
We are developing CD101 topical for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC). CD101 has demonstrated potent fungicidal activity against Candida species in vitro and has unique physical properties allowing its formulation as a topical agent.
Cloudbreak is a proprietary immunotherapy platform being used to create compounds that direct a patient’s immune cells to attack pathogens that cause infectious disease. We are initially focused on developing solutions for the treatment of invasive aspergillosis.